Table I.
Study characteristics and interferon regimens.
| Author (year) | Patient number (IFN/Ctrl) | Study type | Primary treatment | Viral hepatitis | Type | IFN schedule | Cum. dose (MU) | Weeks | Dose/week (MU) | Median follow-up (mo) | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ikeda et al (2000) | 10/10 | RCT | S/A | HCV | IFNβ | 6 MU biw × 36 wk | 432 | 36 | 12 | 25/25 | (27) |
| Kubo et al (2002) | 15/15 | RCT | Surgery | HCV | IFNα | 6 MU qd × 2 wk+ 6 MU tiw × 14 wk+ 6 MU biw × 88 wk | 1,392 | 104 | 13 | 36/30 | (22) |
| Suou et al (2001) | 18/22 | CS | S/A | HCV | IFNα | 6 MU qd × 2 wk+ 6 MU tiw × 22 wk | 480 | 24 | 20 | NA/NA | (37) |
| Miyaguchi et al (2002) | 16/16 | RCT | TACE+ PEI | HCV | IFNα-2b | 3 MU tiw × 16 wk | 104 | 16 | 7 | NA | (38) |
| Shiratori et al (2003) | 49/25 | RCT | Ablation | HCV | IFNα | 6 MU tiw × 48 wk | 864 | 48 | 18 | 85/85 | (39) |
| Lin et al (2007) | 20/10 | RCT | Ablation | HBV(17)/HCV(13) | IFNα-2b | 3 MU tiw × >24 wk or 3×10/mo × 6 mo+ 3×10/3 mo × 18 mo | 212/360 | 24/96 | 9/4 | 27/27 | (14) |
| Chen et al (2012) | 133/135 | RCT | Surgery | HBV (215)/HCV(53) | IFNα-2b | 1–5/1 wk+5 qd × 4 wk+ 5 MU tiw × 48 wk | 835 | 53 | 16 | 63.8/63.8 | (19) |
| Mazzaferro et al (2006) | 76/74 | RCT | Surgery | HCV | IFNα-2b | 3 MU tiw × 48 wk | 432 | 48 | 9 | 45/45 | (4) |
| Sun et al (2006) | 118/118 | RCT | Surgery | HBV | IFNα-1b | 5 MU qd × 2+ tiw × 72 wk | 1,092 | 74 | 15 | 36.5/36.5 | (18) |
| Lo et al (2007) | 40/40 | RCT | Surgery | HBV (77)/HCV(3) | IFNα-2b | 10 MU/m2 tiw × 16 wk or 30 MU/m2 tiw × 16 wk | 480/1,440 | 16/16 | 30/90 | >36/>36 | (13) |
| Jeong et al (2007a) | 42/42 | CS | S/A | HCV | IFNα | 6 MU qd × 2 wk+ 6 MU tiw × 22 wk | 480 | 24 | 20 | 37/37 | (40) |
| Jeong et al (2007b) | 16/16 | CS | S/A | HCV | IFNα | 3 MU tiw × 48 wk | 432 | 48 | 9 | 32/31 | (20) |
| Kudo et al (2007) | 43/84 | CS | Ablation | HCV | IFNα-2b/PEG-IFNα-2a | Maintenance 3 MU/90 μg qw/q2wk | NA | NA | NA | NA | (21) |
| Hagihara et al (2011) | 37/145 | CS | S/A | HCV | PEG-IFNα-2a/2 | 90–180 μg qw × 24–48 wk (60–100 μg qw × 24–48 wk) | NA | 48 | NA | 44/44 | (41) |
IFN, interferon; Ctrl, control; cum., cumulative; wk, week; mo, months; RCT, randomized controlled trial; S/A, surgery/ablation; HCV, hepatitis C virus; MU, million units; biw, biweekly; qd, once a day; tiw, three times per week; qw, once per week; q2wk, once every 2 weeks; CS, cohort study; TACE, transarterial chemoembolization; PEI, percutaneous ethanol injection; HBV, hepatitis B virus; NA, not available; PEG-IFN, pegylated IFN.